Innoviva Retained Earnings (Accumulated Deficit) 2010-2024 | INVA
Innoviva retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Innoviva Annual Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2023 |
$-25 |
| 2022 |
$-205 |
| 2021 |
$-456 |
| 2020 |
$-722 |
| 2019 |
$-946 |
| 2018 |
$-1,104 |
| 2017 |
$-1,499 |
| 2016 |
$-1,633 |
| 2015 |
$-1,692 |
| 2014 |
$-1,674 |
| 2013 |
$-1,505 |
| 2012 |
$-1,335 |
| 2011 |
$-1,316 |
| 2010 |
$-1,201 |
| 2009 |
$-1,117 |
Innoviva Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2024-09-30 |
$-22 |
| 2024-06-30 |
$-23 |
| 2024-03-31 |
$11 |
| 2023-12-31 |
$-25 |
| 2023-09-30 |
$-87 |
| 2023-06-30 |
$-169 |
| 2023-03-31 |
$-170 |
| 2022-12-31 |
$-205 |
| 2022-09-30 |
$-137 |
| 2022-06-30 |
$-402 |
| 2022-03-31 |
$-403 |
| 2021-12-31 |
$-456 |
| 2021-09-30 |
$-466 |
| 2021-06-30 |
$-539 |
| 2021-03-31 |
$-628 |
| 2020-12-31 |
$-722 |
| 2020-09-30 |
$-776 |
| 2020-06-30 |
$-804 |
| 2020-03-31 |
$-881 |
| 2019-12-31 |
$-946 |
| 2019-09-30 |
$-992 |
| 2019-06-30 |
$-1,032 |
| 2019-03-31 |
$-1,070 |
| 2018-12-31 |
$-1,104 |
| 2018-09-30 |
$-1,367 |
| 2018-06-30 |
$-1,415 |
| 2018-03-31 |
$-1,469 |
| 2017-12-31 |
$-1,499 |
| 2017-09-30 |
$-1,557 |
| 2017-06-30 |
$-1,581 |
| 2017-03-31 |
$-1,616 |
| 2016-12-31 |
$-1,633 |
| 2016-09-30 |
$-1,658 |
| 2016-06-30 |
$-1,673 |
| 2016-03-31 |
$-1,688 |
| 2015-12-31 |
$-1,692 |
| 2015-09-30 |
$-1,697 |
| 2015-06-30 |
$-1,692 |
| 2015-03-31 |
$-1,684 |
| 2014-12-31 |
$-1,674 |
| 2014-09-30 |
$-1,658 |
| 2014-06-30 |
$-1,636 |
| 2014-03-31 |
$-1,573 |
| 2013-12-31 |
$-1,505 |
| 2013-09-30 |
$-1,455 |
| 2013-06-30 |
$-1,408 |
| 2013-03-31 |
$-1,372 |
| 2012-12-31 |
$-1,335 |
| 2012-09-30 |
$-1,303 |
| 2012-06-30 |
$-1,268 |
| 2012-03-31 |
$-1,231 |
| 2011-12-31 |
$-1,316 |
| 2011-09-30 |
$-1,279 |
| 2011-06-30 |
$-1,248 |
| 2011-03-31 |
$-1,223 |
| 2010-12-31 |
$-1,201 |
| 2010-09-30 |
$-1,181 |
| 2010-06-30 |
$-1,160 |
| 2010-03-31 |
$-1,139 |
| 2009-12-31 |
$-1,117 |
| 2009-09-30 |
$-1,095 |
| 2009-06-30 |
$-1,072 |
| 2009-03-31 |
$-1,051 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$1.195B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
